MedTrace Logo

Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma

NCT02507076 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2015-07-23

No results posted yet for this study

Summary

This pilot clinical trial studies isolated limb perfusion with melphalan in treating patients with stage IIIB-IV melanoma or sarcoma. Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Heating a chemotherapy solution and infusing it directly into the arteries around the tumor may kill more tumor cells.

Conditions

  • Basal Cell Carcinoma of the Skin
  • Eccrine Carcinoma of the Skin
  • Recurrent Adult Soft Tissue Sarcoma
  • Recurrent Melanoma
  • Recurrent Skin Cancer
  • Squamous Cell Carcinoma of the Skin
  • Stage III Adult Soft Tissue Sarcoma
  • Stage IIIB Melanoma
  • Stage IIIC Melanoma
  • Stage IV Adult Soft Tissue Sarcoma
  • Stage IV Melanoma

Interventions

DRUG

isolated limb perfusion

Undergo ILP with melphalan

DRUG

melphalan

Undergo ILP with melphalan

PROCEDURE

quality-of-life assessment

Ancillary studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Albert Einstein College of Medicine

    lead OTHER

Principal Investigators

  • Katia Papalezova · Albert Einstein College of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02507076 on ClinicalTrials.gov